Details

Autor(en) / Beteiligte

• Ho, Vincent T
• St. Martin, Andrew
• Pérez, Waleska S
• Steinert, Patricia
• Zhang, Mei-Jie
• Chirnomas, Deborah
• Hoang, Caroline J
• Loberiza, Fausto R
• Saber, Wael

Titel

Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: a CIBMTR Analysis

Ist Teil von

• Biology of blood and marrow transplantation, 2019-12, Vol.26 (5), p.884-892

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Gemtuzumab ozogamicin (GO) therapy prior to allogeneic hematopoietic cell transplantation (alloHCT) has been historically associated with an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with acute myeloid leukemia (AML). The current analysis examined VOD/SOS risk and outcomes in a cohort of patients who in recent years reported to the Center for International Blood & Marrow Transplant Research. Adults with AML who had GO exposure prior to myeloablative alloHCT were matched 1:4 by age and disease status at transplant to recipients without GO exposure (controls). A total of 137 patients with GO exposure and 548 matched controls who underwent alloHCT between 2008 and 2011 were included in this analysis. With a median ~8-year follow-up of survivors, the 5-year overall survival probability was similar in the 2 cohorts: 38% and 38% in the GO-exposed versus control ( P = .97) group. Incidence of VOD/SOS and severe VOD/SOS, respectively, at 100 days was 4% (95% confidence interval [CI]: 1–7) and 3% (95% CI: 1–6) in GO-exposed patients and 3% (95% CI: 2–5) and 1% (95% CI: 0–2) in controls. Correspondingly, among patients who developed VOD/SOS, 1-year survival probability after VOD/SOS diagnosis was 33% (95% CI: 5–72) and 27% (95% CI: 11–47) ( P = .78). In multivariate analyses, GO exposure prior to alloHCT was not associated with an increased risk of VOD/SOS (odds ratio 1.10; P = .85) or death (hazard ratio 1.08; P = .57). Three (3%) deaths in the GO group and 3 (<1%) deaths in the control group were attributed to VOD/SOS. Our results suggest that GO treatment prior to myeloablative alloHCT in the recent era is not associated with an increased risk of post-transplant VOD/SOS or death.